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Introduction: Recent studies suggest that medically treated patients with inoperable chronic
thromboembolic pulmonary hypertension (CTEPH) have an improved prognosis. However, only
limited data are available concerning predictors of mortality in these patients. The aim of this
study was to assess, and to identify, predictors of the long-term outcome of inoperable CTEPH
patients.
Methods: We analysed 84 inoperable CTEPH patients referred to our centre between 1999 and
2008. During follow-up (mean 32 months), 17 patients died and one underwent a lung trans-
plantation. The 1-, 3- and 5-year survival rates were 93, 78 and 68%, respectively. Univariate
analysis demonstrated that 6-min walking distance (6MWD), mean pulmonary artery pressure
(mPAP), right atrial pressure (RAP) and pulmonary vascular resistance (PVR) were predictive
factors for survival. In the multivariate analysis only 6MWD was independently related to poor
survival (hazard ratio 0.995; 95% CI, 0.991e0.998; PZ 0.003). KaplaneMeier curves showed
that patients with an mPAP > 40 mmHg, PVR > 584 dyn s cm5 and RAP > 12 mmHg had a very
poor prognosis.
Conclusions: Haemodynamic parameters (mPAP, RAP, PVR) and the 6MWD at baseline are
predictive factors for mortality of medically treated inoperable CTEPH patients. A subgroupdistance; AMC, associated medical conditions; CTEPH, chronic thromboembolic pulmonary hyper-
gonist; mPAP, mean pulmonary artery pressure; NT-proBNP, N-terminal pro brain natriuretic peptide;
inhibitor; PVR, pulmonary vascular resistance; PEA, pulmonary endarterectomy; RAP, right atrial
racteristics; RVP, right ventricular pressure; SvO2, mixed venous oxygen saturation.
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1014 N. Saouti et al.Table 1 Baseline parameters be
Variable
Age (years)
Female/male ratio (n)
Functional class NYHA (%)
I, II, III or IV
RAP (mmHg)
Diastolic RVP (mmHg)
mPAP (mmHg)
PVR (dyn s cm5)
Cardiac index (L min1 m2)
SvO2 (%)
SaO2 (%)
6MWD (m)
NT-proBNP (ng L1)
Values are presented as mean  SD.
ciation; RAP, right atrial pressure;
pulmonary vascular resistance; SvO2
natriuretic peptide; ASD, atrial septa
intravenous lines, splenectomy, inflaof these patients with good prognostic factors, defined by their haemodynamics and clinical
measures, have an improved long-term survival and outcome.
Crown Copyright ª 2009 Published by Elsevier Ltd. All rights reserved.Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH)
is an uncommon, although increasingly diagnosed, disease
of the pulmonary artery vasculature characterised by
intraluminal thrombus formation and fibrous stenosis or
complete obliteration.1,2 These obstructions are typically
distributed in the central pulmonary arteries. As a result
patients develop various degrees of pulmonary hyperten-
sion, depending on the extent of the vascular obstructions.
Left untreated, this leads to right ventricular failure and
death.3 Predictive factors for survival in patients with
inoperable CTEPH treated medically have not been suffi-
ciently elucidated.
In recent years medical treatment with proven efficacy
in idiopathic pulmonary arterial hypertension (IPAH) and
other forms of PAH, such as prostacyclin, phosphodies-
terase-5 inhibitors (PDE-5 inhibitors) and endothelin
receptor antagonists (ERA), has been tried in patients with
inoperable CTEPH4e11 sometimes as a therapeutic bridge
to pulmonary endarterectomy (PEA).12,13 Although the
effect of treatment on long-term survival has never been
investigated in a randomised trial, recent data from two
large PAH centres show that long-term survival of medi-
cally treated CTEPH patients is much better than was
reported in earlier studies of untreated patients.14,15
However, it is unclear which parameters predict long-term
survival in this era of PH-specific (oral) medical treatment.
Therefore the aim of this study was to identify the
determinants of survival in medically treated inoperable
CTEPH patients.tween survivors and non-surviv
All (nZ 84) S
64  13 6
59/25 4
4, 26, 45, 25 1
9.4  6.9 8
12  13 1
45  13 4
718  368 6
2.6  .9 2
62  11 6
93  6 9
363  135 3
1702  2278 1
P values refer to comparisons b
Diastolic RVP, diastolic right ven
, mixed venous oxygen saturation
l defect; CAD, coronary artery dis
mmatory bowel disease).Materials and methods
Subjects and study design
This observational cohort study encompassed 84 inoperable
CTEPH patients. All patients were referred to the Depart-
ment of Pulmonary Diseases at the VU Medical Centre (a
specialised referral centre for the evaluation and treat-
ment of PH) between May 1999 and February 2008. Cohort
entry was defined as the time/date of first right heart
catheterisation, to establish the diagnosis of pulmonary
arterial hypertension. See Table 1 for baseline patient
characteristics.Methods
The diagnosis of CTEPH was made using standard diagnostic
criteria.16,17 All patients were evaluated by a multi disci-
plinary team of pulmonary physicians, surgeons and radi-
ologists using ventilation/perfusion scintigraphy, CT
pulmonary angiography, conventional pulmonary angiog-
raphy, and right heart catheterisation. CTEPH patients
were regarded as inoperable when either distal, surgically
inaccessible vascular occlusions were present or when the
severity of the PH was greater than predicted from the
degree of vascular obliteration. In addition, all patients
received a complete work-up to exclude left sided heart
disease by means of echocardiography, and pulmonary
diseases as an underlying cause of the pulmonary hyper-
tension by means of high resolution computed tomographyors with CTEPH.
urvivors (nZ 66) Non-survivors
(nZ 18)
P
4  14 63  12 0.99
7/19 12/6 0.7
00, 91, 90, 43 0, 9, 10, 57 0.0001
 6 14  7.9 0.004
1  14.6 15.9  8.4 0.04
2.9  13.4 53  9.6 0.003
31  312 1015  399 0.0001
.8  .9 2.2  .9 0.03
3  9.6 56  12.8 0.01
3  6 92  4 0.34
90  124 264  131 0.0001
566  2238 3206  2420 0.1
etween survivors and non-survivors. NYHA, New York Heart Asso-
tricular pressure; mPAP, mean pulmonary artery pressure; PVR,
; 6MWD, 6-min walking distance; NT-proBNP, N-terminal pro brain
ease; AMC, associated medical conditions (i.e. permanent central
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work-up all patients were classified according to the NYHA
functional class and all patients (nZ 75) had to perform
a 6-min walk test (6MWD), according to current guide-
lines.18 Blood was taken from a peripheral vein to assess N-
terminal pro brain natriuretic peptide (NT-proBNP) (nZ 60)
analysed on an ELECSYS 1010 bench top analyser (Roche
Diagnostics, Netherlands). Since NT-proBNP measurement
was not available until the end of 2003, this data could not
be obtained in 25 patients. In addition to coumadin
(adjusted to a target international normalised ratio
between 2.0 and 3.0) oxygen and diuretics CTEPH patients
also received PH-specific medications. The pharmacological
treatment varied among patients (see Table 2), depending
on the clinical condition. The introduction of new drugs
during the time course of this study is another source of
treatment variability. In the period after 2003 patients in
NYHA class III received oral therapy as first line. Choice of
oral monotherapy was based on medication availability and
clinical data available at that time.
Statistical analyses
Baseline parameters between survivors and non-survivors
were compared using independent Student’s t-tests. Cate-
gorical data were compared using c2 tests. Univariate
analyses based on the proportional hazard model were used
to examine the relationships between survival and selected
demographic, clinical measures and haemodynamics
measured at baseline. Forward stepwise multivariate anal-
ysis based on the Cox proportional hazard model was used to
examine the independent effect of multiple covariates on
survival, controlling for possible confounders. Optimal cut-
off values assessed with receiver operating curve (ROC)
analysis were used to separate the patients on both sides
into two groups. Survival curves were derived by the
KaplaneMeier method. Groups were compared by the log
rank test.
Survival was estimated from the date of initial diagnosis
until February 5, 2008, the date of death or that of lungTable 2 Treatment with PH-specific drugs and comorbidities in
Variable All (nZ 84) S
Medication
PDE-5 inhibitor 3
ERA
Prostacyclin
Combination PDE-5 þ ERA 1
Combination Pros þ PDE-5
Combination Pros þ PDE-5 þ ERA
Comorbidities
Congenital heart disease (ASD) 5
Cancer 11
CAD 6
COPD 8
Thyroid disease 2
Atrial fibrillation 1
AMC 10
PDE-5 inhibitor, phosphodiesterase-5 inhibitor; ERA, endothelin receptransplantation. A P value <0.05 was considered statisti-
cally significant.
Results
The baseline patient characteristics and haemodynamics are
summarised in Table 1. The mean age was 64  13 years and
the majority of patients were female. The NYHA functional
class II, III and IV is also given in the table. The averaged
exercise capacity expressed in 6MWD was 363  35 m, indi-
cating moderate exercise intolerance. The haemodynamic
parameters showed that patients had significant pulmonary
hypertension with increased RV and RA pressures.
Table 2 shows the treatments and comorbidities in the
inoperable CTEPH patients. The vast majority of survivors
were treated with a PDE-5 inhibitor and in clinically dete-
riorating patients an ERA was added after initial therapy
with a PDE-5 inhibitor. In the non-survivors, prostacyclin
was the most commonly used drug, reflecting the clinical
severity of the condition in these patients. Prostacyclin was
the most commonly used drug before 2003 in contrast to
treatment after 2003 (39% vs. 8% respectively).
Associated medical conditions (AMC) and cancer were
the most common comorbidities.
Differences in parameters between survivors and non-
survivors are also shown in Table 1. The non-survivors had
a significantly worse haemodynamic status at baseline than
survivors (i.e. significantly higher RAP, diastolic RVP, mean
PAP, PVR and significant lower SvO2). The higher pressures
in non-survivors were reflected in a tendency to higher NT-
proBNP values but this did not reach significance due to the
large standard deviation. As expected non-survivors had
a significantly worse NYHA functional class compared to
survivors. The performance in 6MWD was also lower in the
non-survivors (P < 0.0001).
Survival
During a mean observation time of 32  20 months (range
0e87 months) no patients were censored for reasons otherpatients with CTEPH.
urvivors (nZ 66) Non-survivors (nZ 18) P
3 1 e
4 1 e
3 7 e
5 3 e
0 4 e
1 1 e
5 0
7 4
6 0
8 0
2 0
1 0
6 4
tor antagonist; Prost, prostacyclin.
1016 N. Saouti et al.than death. From the 84 patients 17 patients (20%) died
from right heart failure (nZ 13), and respiratory failure in
the end stage of right heart failure (nZ 4). At 2 years one
patient had undergone lung transplantation.
The 1-, 3- and 5-year survival for the total cohort was 93,
78 and 68%, respectively.
Although survival was significantly better after 2003
compared with the survival before 2003, with 1-, 3- and 5-
year survival rates of 97, 84 and 79% vs. 71, 50 and 43%
respectively, patients at clinical presentation in the period
before 2003 had more severe disease as reflected by their
haemodynamics (mPAP 51  9 vs. 44  14, PZ 0.02; PVR
924  427 vs. 686  353, PZ 0.03).
Univariate analysis
Table 3 shows the results of the univariate Cox proportional
hazards regression analysis. Of the haemodynamic variables
mPAP, RAP and PVR were associated with poor survival, and
of the clinical variables only 6MWD was significantly related
to an increased risk of death. The hazard ratio for a 50-m
difference in 6MWD was 0.779 (95% CI; 0.640e0.947) and
for a 100 dyn s cm5 difference in PVR 1.221 (95% CI:
1.004e1.486).
Mortality was not associatedwith patient age, NT-proBNP,
mixed venous oxygen saturation, cardiac index, NYHA func-
tional class and associated medical conditions (AMC).
Receiver-operating characteristics (ROC)
To distinguish survivors from non-survivors according to
baseline parameters, an ROC analysis was performed with
the significant predictors from the univariate analysis.
Groups were created based on the optimal cut-off values
determined by ROC analysis and KaplaneMeier curves were
compared for the different groups.Table 3 Univariate Cox proportional hazard analysis of
variables associated with mortality in inoperable CTEPH
(nZ 84).
Variable Hazard ratio 95% CI P
Age (years) 0.996 0.963e1.030 0.82
6MWD (m) [per 50 m
increase in distance]
0.779 0.640e0.947 0.003
NT-proBNP (ng L1) 1.000 1.000e1.000 0.22
NYHA I, II vs. III, IV 3.044 0.700e13.226 0.14
mPAP (mmHg) 1.038 1.003e1.074 0.034
PVR (dyn s cm5)
[per 100 dyn
increase in
resistance]
1.221 1.004e1.486 0.004
SvO2 (%) 0.974 0.938e1.012 0.18
CI (L min1 m2) 0.599 0.322e1.116 0.11
RAP (mmHg) 1.072 1.009e1.140 0.025
AMC 2.307 0.740e7.187 0.149
NYHA class is dichotomised comparing classes I and II with
classes III and IV. CI, confidence interval; AMC, associated
medical conditions (i.e. splenectomy, permanent central
intravenous lines, and inflammatory disorders).Patients with a 6MWD less than 298 m had a significantly
lower survival rate than those with a 6MWD more than
298 m (log rank test, P < 0.009; Fig. 1a). Separation of the
groups using the median 6MWD of 386 m was significantly
less predictive than when using the optimal cut-off value of
298 m determined by the ROC analysis (data not shown).
The same KaplaneMeier curves showed that patients with
an mPAP > 40 mmHg, RAP > 12 mmHg and, PVR > 584 dyn s
cm5 were at a significantly higher risk of death compared
with patients who had an mPAP < 40 mmHg (P < 0.02),
RAP < 12 mmHg (PZ 0.009), and PVR < 584 dyn s cm5
(PZ 0.002) respectively (Fig. 1b,c,d).
Multivariate analysis
In the forward stepwise multivariate analysis, we examined
the effect on mortality of each independent baseline
variable in the presence of others. All independent vari-
ables found to be significant in the univariate analysis were
included. Only 6MWD was independently related to poor
survival (hazard ratio 0.995; 95% CI, 0.991e0.998;
PZ 0.003). Backward multivariate analysis showed the
same outcome.
Discussion
We found that haemodynamic parameters (i.e. mPAP, RAP,
PVR) and the 6MWD at baseline are strongly related to long-
term outcome and survival in CTEPH patients with inoper-
able disease.
Survival
Data on long-term survival in inoperable CTEPH patients
before modern vasoactive treatment were very poor. The
only two studies describing survival in medically untreated
CTEPH patients showed that the 3-year survival rate was as
low as 10% in patients with a mean PAP > 30 mmHg19 and
the 5 year survival 14% in patients with a mean
PAP > 50 mmHg.3 In our present study, with modern treat-
ment, the overall 1-, 3- and 5-year survival was 93, 78 and
68%, respectively. These survival rates are comparable with
recently published studies of Bonderman and Condliffe
et al.14,15 In the study of Bonderman et al. 1-, 3- and 5-year
survival was 88, 65 and 65% respectively, although these
were patients without associated medical conditions. With
associated medical conditions these inoperable CTEPH
patients had poorer 1-, 3- and 5-year survivals of 74, 45 and
15%. Condliffe et al. showed in a national study of medi-
cally treated inoperable CTEPH patients from the United
Kingdom 1-, 3- and 5-year survival of 82, 70 and 55%
respectively.15
Prognostic factors
In IPAH, cardiac index, degree of RAP and PAP elevation are
associated with survival.20 In CTEPH few data are available
about prognostic factors of survival with modern vasoactive
therapy. In previous studies of medically untreated CTEPH
patients the degree of mPAP was a strong predictor of
mortality.3,19 In our present study of inoperable CTEPH
A B
C D
Figure 1 KaplaneMeier curves according to the optimal cut-off value derived by ROC analysis for 6-min walking distance (6MWD;
panel A); mean pulmonary artery pressure (mPAP, panel B); right atrial pressure (RAP, panel C); and pulmonary vascular resistance
(PVR, panel D).
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are able to predict long-term survival. A low mPAP, PVR and
RAP at baseline (all below the cut-off value determined by
ROC analysis) were beneficial in prognosis for these patients.
Of the clinical variables a relatively high 6MWD of 298 m was
associated with a better long-term survival. It is somewhat
unexpected that mPAP is a predictive factor for survival in
PH, since in the end stage of the disease mPAP decreases
while the disease progresses. However, our data are in
agreementwith those reported by Riedel et al.3 and Lewczuk
et al.19 that also showed an association between mPAP and
mortality.Other survival studies in patientswith PHhave also
shownanassociationbetweenmPAPandmortality.20,21 It can
be expected that patients in NYHA class 3 or 4 with a low
mPAP (indicating very severe or end-stage disease) have
a worse survival than patients in NYHA class 1 or 2 with a high
mPAP (indicating less advanced disease). We did an addi-
tional analysis to check this and, surprisingly, the hazard
ratio for mPAP when adjusted for the dichotomised NYHA
class 1 and 2 versus class 3 and 4 (HR 1.040; 95% CI 1.000e
1.081), is the same as the hazard ratio for mPAP alone (HR
1.038; 95% CI 1.003e1.074). This finding indicates that the
stage of the disease is not a confounder in this study.Bonderman et al. showed that associated medical
conditions (AMC) are related to increased mortality.14 In
our present study four of the 10 patients with AMC (40%)
died. The reason that AMC was found not to be significant in
the univariate analysis is probably due to the low number of
deaths in the total cohort of patients. Although univariate
analysis showed that survival is worse in the period before
2003 at the time when only prostacycline was available,
multivariate analysis showed that this variable was not
significant, most probably since patients diagnosed with
CTEPH had more severe disease reflected by their haemo-
dynamics in comparison to the patient group diagnosed
after 2003.
In the ‘‘survivor’’ group, 10 of the 66 patients did not
receive PH-specific drug therapy because of mild symptoms
and/or pulmonary haemodynamics, and only one of the 18
‘‘non-survivors’’ did not receive this drug therapy because
it was contraindicated in this patient. Hence, it seems that
these medications were not necessarily more beneficial for
survival as those patients who did not receive these drugs
were not more likely to die during follow-up. However, due
to the low number of events in the non-survivor group
a relationship between drug therapy and survival could not
1018 N. Saouti et al.be reliably tested in the univariate analysis. Therefore, it
was unlikely that our present study would demonstrate
a survival benefit from PH-specific drug therapy, even if
such a benefit exists. This is in agreement with the recent
article by Condliffe et al.22
The present study demonstrates that the 6MWD is the
only independent factor that predicts survival. Patients
with a 6MWD more than 298 m had a significantly better
long-term survival than patients walking less. This finding is
in accordance with the study by Myamoto in IPAH showing
that 6MWD is a strong independent factor associated with
mortality.23 Miyamoto et al. assessed the cut-off value by
the median and found that IPAH patients walking more than
332 m had a significantly better survival. Another study
showed that with ROC analysis a preoperative
6MWD  345 m was able to predict death in patients who
had undergone pulmonary endarterectomy with a sensi-
tivity of 100% and specificity of 36%.24 Using the cut-off
value of 298 m in our study, as determined by ROC analysis,
provided the best discrimination between survivors and
non-survivors.
Clinical implication
We have tried to provide a profile of the survivors and
non-survivors with both clinical measures and haemody-
namics evaluated at baseline. Although it is clear that the
treatment of choice is pulmonary endarterectomy (PEA) in
patients with CTEPH suitable for surgery, the indications
for surgery are not always so clear since the degree of
vascular obstruction on angiography is often not corre-
lated to haemodynamic and clinical severity. The prog-
nostic haemodynamic (mPAP, PVR and RAP) and clinical
(6MWD) factors in our present study can be used for risk
stratification in CTEPH patients with inoperable disease
for the decision-making process regarding the treatment
options.
The main limitation of this study is its retrospective
observational design. As a result of this we miss some NT-
proBNP data. This study concerns only inoperable CTEPH
patients and therefore results cannot be applied to
patients with operable CTEPH patients. Another limitation
is the small number of events, therefore the results of the
multivariate analysis should be interpreted with caution.
Nonetheless, 6MWD remains a strong independent
predictor for mortality. Finally, our patients were very
heterogeneously treated, according to newly introduced
drugs over the years, and the available clinical insights.
Since it was not the aim of this study to prove that medical
treatment is beneficial in CTEPH, nor to study the differ-
ences in efficacy between treatment strategies, no
conclusions can be drawn on the optimal treatment
schedule. Due to the observational nature of this study,
a suggestion for improvements in survival cannot be given.
Prospective research with the aim of investigating the
optimal treatment scheme in these patients with inoper-
able disease is needed.
Conclusions
Long-term survival and outcome of medically treated
CTEPH patients with inoperable diseases is much improved
in this therapeutic era compared with untreated patientsand is comparable with recently reported survival rates.
Severity at baseline, assessed by haemodynamics and
clinical measures, predicts the survival of these patients. A
6MWD above 298 m at baseline is associated with a favour-
able long-term survival and is simple to determine.
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